ReviewEmerging infectious diseases2025
Preparedness and Response Considerations for High-Consequence Infectious Disease.
Review in Emerging infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Autopsy practices for high-consequence infectious diseases: global guidelines, alternatives, and the BSL-4 gap.Emerging microbes & infections · 2026Review
- Research hotspots and trend analyses of maximum biosafety level pathogens: A bibliometric study using China's 2023 catalogue of pathogens as an example.Biosafety and health · 2026Article
- Clinician Obligations to Care for Patients Infected With Special Pathogens.JAMA network open · 2026Article
- Point-of-care routine laboratory testing for patients with suspected viral hemorrhagic fevers.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2026Review
- Sports fever! Getting the ball rolling to prevent infections at the World Cup™ and beyond.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-consequence infectious diseases (HCIDs) are acute human infectious diseases with high illness and case-fatality rates, few or no available effective treatment or prevention options, and the ability to spread in the community and within healthcare settings. Those characteristics lead to significant risks to patients and their close contacts, healthcare workers, laboratory personnel, and communities exposed to an outbreak. We describe aspects of healthcare system preparedness for and response to HCIDs, including the role of high-level isolation units, ensuring safe clinical laboratory capabilities and waste management, increasing availability of medical countermeasures, coordinating with stakeholders and systems of care, and communicating with the public. Finally, we discuss priority areas for further investment in HCID preparedness, care, and research. Effective and equitably disseminated medical countermeasures for HCIDs are urgently needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.